Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.